2[1]Isaacs C,Robert NJ,Bailey FA,et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin [J]. J Clin Oncol, 1997, 15:3368- 3377.
3[2]John W, Smith H. Tolerability and side-effect profile of rhIL-11 [J]. Oncology,2000,14(9):41- 47.
4Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for plateht transfusions in patients with gynecologic cancer. Ann Intern Med, 2000, 132:364-368.
5Kaushansky K. Use of thrombopoietic growth factors in acute leukemia. Leukemia, 2000, 14:505-508.
6Cantor SB, Ehing LS, Hudson DV Jr, et al. Pharmacoeconomic analysis of oprelvekin ( recombinant human interleukin-11 ) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer, 2003, 97:3099-3106.
